TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18684279

Group type: EXPERIMENTAL
Intervention: DDDR pacing (dual chamber pacing)
Number of subjects: 504

Group type: COMPARATOR
Intervention: VVI pacing (single chamber pacing)
Number of subjects: 504
Study: 15801938

Group type: EXPERIMENTAL
Intervention: Gemfibrozil 600 mg twice daily for 8 days
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 12579599

Group type: EXPERIMENTAL
Intervention: 12 cyclophosphamide (CY) pulses combined with corticosteroids (CS)
Number of subjects: 65

Group type: COMPARATOR
Intervention: 6 cyclophosphamide (CY) pulses combined with corticosteroids (CS)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (6 CY pulses)
Number of subjects: 65
Study: 10233489

Group type: EXPERIMENTAL
Intervention: Hybrid laser treatment (30 W KTP and 60 W Nd:YAG)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 204
Study: 9106842

Group type: EXPERIMENTAL
Intervention: Verbal encouragement
Number of subjects: 26

Group type: COMPARATOR
Intervention: No verbal encouragement
Number of subjects: 26
Study: 1491486

Group type: EXPERIMENTAL
Intervention: 99mTc-teboroxime (TEBO)
Number of subjects: 194

Group type: COMPARATOR
Intervention: 201Tl
Number of subjects: 194
Study: 2858747

Group type: EXPERIMENTAL
Intervention: Impedance monitoring
Number of subjects: 6

Group type: COMPARATOR
Intervention: Scintigraphy
Number of subjects: 6
Study: 31739840

Group type: EXPERIMENTAL
Intervention: Montelukast sodium chewable tablets combined with inhaled budesonide
Number of subjects: 135

Group type: COMPARATOR
Intervention: Single-drug group (either montelukast sodium or budesonide)
Number of subjects: 135
Study: 30400840

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Endurance Training (HIIT)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo intervention (supervised myofascial release training)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: HIIT
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo intervention
Number of subjects: 59
Study: 26371459

Group type: EXPERIMENTAL
Intervention: Indoor training
Number of subjects: 23

Group type: COMPARATOR
Intervention: Outdoor training
Number of subjects: 23
Study: 24595505

Group type: EXPERIMENTAL
Intervention: Nicotine patches
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Moderate decreasers
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Strong decreasers
Number of subjects: 265

Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 265
Study: 22076751

Group type: EXPERIMENTAL
Intervention: Atorvastatin (40 mg/day for 14 days)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 17655985

Group type: EXPERIMENTAL
Intervention: Immersion bath for 60 mins
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control (non-bathing)
Number of subjects: 108
Study: 17615478

Group type: EXPERIMENTAL
Intervention: Exercise program (8 weeks, 35 minutes per session, 4 times per week)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 39
Study: 15090794

Group type: EXPERIMENTAL
Intervention: HLA-G*0105N allele
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: HLA-G*010108 allele
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: HLA-G*010108/010401 genotype
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: HLA-G*010101/010108 genotype
Number of subjects: 431
Study: 11438814

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (rHuEPO) in allogeneic stem cell transplantation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Recombinant human erythropoietin (rHuEPO) in autologous stem cell transplantation
Number of subjects: 0
Study: 8486041

Group type: EXPERIMENTAL
Intervention: Continuous turning on an oscillating air-flotation bed for five days
Number of subjects: 124

Group type: COMPARATOR
Intervention: Routine turning on a standard ICU bed for five days
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Continuous turning on an oscillating air-flotation bed for five days (specifically in SEPSIS DRG)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Routine turning on a standard ICU bed for five days (specifically in SEPSIS DRG)
Number of subjects: 124
Study: 3154674

Group type: EXPERIMENTAL
Intervention: Nisoldipine 10 mg once a day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 0
Study: 31927665

Group type: EXPERIMENTAL
Intervention: Internal cardioversion through ICD
Number of subjects: 31

Group type: COMPARATOR
Intervention: External direct current cardioversion (EDCCV)
Number of subjects: 31
Study: 29748195

Group type: EXPERIMENTAL
Intervention: High-intensity exercise training for 10 months
Number of subjects: 61

Group type: COMPARATOR
Intervention: Yoga (control group)
Number of subjects: 61
Study: 28784181

Group type: EXPERIMENTAL
Intervention: Low-fructose diet intervention group (LFDI)
Number of subjects: 490

Group type: COMPARATOR
Intervention: Standard-diet control group (SDC)
Number of subjects: 490
Study: 26240230

Group type: EXPERIMENTAL
Intervention: recombinant human TSH (rhTSH)
Number of subjects: 752

Group type: COMPARATOR
Intervention: thyroid hormone withdrawal (THW)
Number of subjects: 752

Group type: EXPERIMENTAL
Intervention: 1.1 GBq of (131)I
Number of subjects: 752

Group type: COMPARATOR
Intervention: 3.7 GBq of (131)I
Number of subjects: 752
Study: 24116723

Group type: EXPERIMENTAL
Intervention: Subthalamic nucleus (STN) stimulation
Number of subjects: 12

Group type: COMPARATOR
Intervention: Globus pallidus internus (GPi) stimulation
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Simultaneous stimulation of STN and GPi
Number of subjects: 12

Group type: COMPARATOR
Intervention: GPi stimulation (in patients rated according to TWSTRS)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: STN stimulation (in patients rated according to TWSTRS)
Number of subjects: 12
Study: 21974695

Group type: EXPERIMENTAL
Intervention: High hemoglobin target (11.0‐13.0g/dL) with darbepoetin alfa
Number of subjects: 321

Group type: COMPARATOR
Intervention: Low hemoglobin target (9.0‐11.0g/dL) with recombinant erythropoietin
Number of subjects: 321
Study: 18082498

Group type: EXPERIMENTAL
Intervention: Class IC antiarrhythmic drugs (AADs)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Amiodarone
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Class IC AADs
Number of subjects: 176
Study: 16441978

Group type: EXPERIMENTAL
Intervention: Intravenous tramadol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ketorolac
Number of subjects: 60
Study: 14572748

Group type: EXPERIMENTAL
Intervention: Strontium(89) Chloride (150MBq, single intravenous injection)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Local field radiotherapy (usual regimen used at each centre)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Strontium(89) Chloride
Number of subjects: 203

Group type: COMPARATOR
Intervention: Local field radiotherapy
Number of subjects: 203
Study: 10594429

Group type: EXPERIMENTAL
Intervention: Pressure group with narrow cuff (7 cm)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Pressure group with wide cuff (14 cm)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Saturation group with narrow cuff (7 cm)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Saturation group with wide cuff (14 cm)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Pressure group (both cuffs)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saturation group (both cuffs)
Number of subjects: 20
Study: 9294900

Group type: EXPERIMENTAL
Intervention: Preunit interactions
Number of subjects: 0
Study: 8473450

Group type: COMPARATOR
Intervention: 225 IU HMG/day
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: 450 IU HMG/day
Number of subjects: 46
Study: 3608048

Group type: EXPERIMENTAL
Intervention: Enflurane in N2O/oxygen, and fentanyl (Group II)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Enflurane in air/oxygen, and fentanyl (Group I)
Number of subjects: 20
Study: 30646139

Group type: EXPERIMENTAL
Intervention: Home blood pressure telemonitoring with pharmacist management
Number of subjects: 450

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 450
Study: 30402599

Group type: EXPERIMENTAL
Intervention: Partial whey hydrolysate infant formula
Number of subjects: 2252

Group type: EXPERIMENTAL
Intervention: Extensive whey hydrolysate infant formula
Number of subjects: 2252

Group type: EXPERIMENTAL
Intervention: Extensive casein hydrolysate infant formula
Number of subjects: 2252

Group type: COMPARATOR
Intervention: Standard cow's milk formula
Number of subjects: 2252
Study: 23557321

Group type: EXPERIMENTAL
Intervention: Context-specific behaviour change strategy to improve child nutrition
Number of subjects: 750
Study: 24074642

Group type: EXPERIMENTAL
Intervention: Dolutegravir (50 mg once daily)
Number of subjects: 822

Group type: COMPARATOR
Intervention: Raltegravir (400 mg twice daily)
Number of subjects: 822
Study: 21222223

Group type: EXPERIMENTAL
Intervention: Flexibility-toning-balance exercise
Number of subjects: 179

Group type: COMPARATOR
Intervention: Walking exercise
Number of subjects: 179
Study: 19062012

Group type: COMPARATOR
Intervention: Low-dose oral contraceptive alone
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Low-dose oral contraceptive combined with a GnRH analog
Number of subjects: 58
Study: 17925591

Group type: EXPERIMENTAL
Intervention: AMG 531 (0.3, 1, or 2 microg/kg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: AMG 531 (1 microg/kg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: AMG 531 (2 microg/kg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 15026950

Group type: EXPERIMENTAL
Intervention: Part-body hyperthermia with a radiofrequency multiantenna applicator (BSD 2000/3D) under MR monitoring
Number of subjects: 33
Study: 11722711

Group type: EXPERIMENTAL
Intervention: Topical clobetasol propionate ointment (0.05%) applied three times a day
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Clobetasol propionate in an adhesive denture paste (1:1) applied two times a day
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Clobetasol propionate in an oral analgesic base (Orabase‐B) (1:1) applied two times a day
Number of subjects: 54
Study: 8989238

Group type: EXPERIMENTAL
Intervention: GH therapy (12.5 micrograms/kg per day)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: GH therapy
Number of subjects: 173
Study: 8480572

Group type: EXPERIMENTAL
Intervention: Continuous preprocedural heparinization for > or = 12 hours
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no preprocedural heparin)
Number of subjects: 0
Study: 2953219

Group type: EXPERIMENTAL
Intervention: Nafazatrom 800 mg four times daily for 1 week
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nafazatrom 1600 mg four times daily for 1 week
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nafazatrom treatment
Number of subjects: 12
Study: 29769450

Group type: EXPERIMENTAL
Intervention: HSPPC‐96 vaccination in combination with standard treatment after surgical resection
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: HSPPC‐96 vaccination
Number of subjects: 20
Study: 26519244

Group type: EXPERIMENTAL
Intervention: Right-ventricle-to-pulmonary-artery shunt (RVPAS)
Number of subjects: 323

Group type: COMPARATOR
Intervention: Modified Blalock-Taussig shunt (MBTS)
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Deep hypothermic circulatory arrest
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Pre-Fontan complications
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Age at stage II
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: At least moderate tricuspid regurgitation
Number of subjects: 323
Study: 25415811

Group type: EXPERIMENTAL
Intervention: Fibrinogen concentrate (30mg/kg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 30
Study: 24351700

Group type: EXPERIMENTAL
Intervention: Weight loss intervention
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Weight loss intervention (≥10% body weight loss)
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Change in weight
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Baseline level of the biomarker
Number of subjects: 417
Study: 19395425

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 157

Group type: COMPARATOR
Intervention: Nortriptyline
Number of subjects: 157
Study: 18391619

Group type: EXPERIMENTAL
Intervention: New prognostic classification based on residual disease after neoadjuvant chemotherapy
Number of subjects: 710
Study: 15879583

Group type: EXPERIMENTAL
Intervention: TSD + paroxetine
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: TSD + PBO
Number of subjects: 80

Group type: COMPARATOR
Intervention: paroxetine alone
Number of subjects: 80
Study: 14526714

Group type: EXPERIMENTAL
Intervention: CHM extract capsule (containing 18 herbs), given daily for 8 weeks
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo, given daily for 8 weeks
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: CHM extract capsule
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 10392679

Group type: EXPERIMENTAL
Intervention: Ultrafiltration (UF group; n = 21)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (n = 22)
Number of subjects: 43
Study: 8879380

Group type: EXPERIMENTAL
Intervention: Oral ifosfamide (OSI) at a dose of 1 g/day for 14 days every 4 weeks
Number of subjects: 68

Group type: COMPARATOR
Intervention: Intravenous ifosfamide (IVI) at a dose of 1.6 g/m2/day for 5 days every 4 weeks
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Oral ifosfamide (OSI)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Intravenous ifosfamide (IVI)
Number of subjects: 68
Study: 1848054

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (Enoxaparin), 30 mg subcutaneously twice daily for 14 days or until discharge.
Number of subjects: 665

Group type: COMPARATOR
Intervention: Standard calcium heparin, 7500 units subcutaneously twice daily for 14 days or until discharge.
Number of subjects: 665
Study: 6395416

Group type: EXPERIMENTAL
Intervention: Electromyographic biofeedback
Number of subjects: 30

Group type: COMPARATOR
Intervention: Occlusal appliances (splints)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Biofeedback training
Number of subjects: 30

Group type: COMPARATOR
Intervention: Night-time use of stabilisation splints
Number of subjects: 30

Group type: COMPARATOR
Intervention: Night-time use of bite plates
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: TMAS scores (anxiety level)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: EMG activity in masseter and temporal muscles
Number of subjects: 30
Study: 31022366

Group type: EXPERIMENTAL
Intervention: Hearing aids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination instruments (hearing aids with a built-in sound generator)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 29651778

Group type: EXPERIMENTAL
Intervention: Telephone follow-up administered by specialist nurses
Number of subjects: 259

Group type: COMPARATOR
Intervention: Standard hospital outpatient follow-up
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Telephone follow-up
Number of subjects: 259
Study: 26849442

Group type: EXPERIMENTAL
Intervention: Direct observation of treatment (DOT) provided by a family member
Number of subjects: 624

Group type: COMPARATOR
Intervention: Direct observation of treatment (DOT) provided by a non-family member (usual-practice)
Number of subjects: 624
Study: 24467828

Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen (1 to 3 years)
Number of subjects: 563

Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 563
Study: 22781788

Group type: EXPERIMENTAL
Intervention: VMS frequency (24-hour, day, and night)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: VMS frequency (24-hour)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Day VMS frequency
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Night VMS frequency
Number of subjects: 145
Study: 20100767

Group type: EXPERIMENTAL
Intervention: Treatment of both clinical seizures and subclinical seizure patterns (group A)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (blinding of aEEG registration and treatment of clinical seizures only, group B)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (group B)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Treatment group (group A)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 33
Study: 16200053

Group type: EXPERIMENTAL
Intervention: Early trabeculectomy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional medical management
Number of subjects: 60

Group type: COMPARATOR
Intervention: Educational package about glaucoma
Number of subjects: 60
Study: 12898290

Group type: EXPERIMENTAL
Intervention: Lichtenstein repair
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: McVay repair
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Shouldice repair
Number of subjects: 150
Study: 11513014

Group type: EXPERIMENTAL
Intervention: Education intervention (viewing a video on AD, reading written information about the disease, or both)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no education intervention)
Number of subjects: 100
Study: 9573908

Group type: EXPERIMENTAL
Intervention: Self-help course
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Uncertainty management
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Self-help course plus uncertainty management
Number of subjects: 193

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 193
Study: 7835776

Group type: COMPARATOR
Intervention: Loop excision (n = 38)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Cold-knife conization (n = 52)
Number of subjects: 90
Study: 2899840

Group type: EXPERIMENTAL
Intervention: Diltiazem (240 mg per day, n = 1234)
Number of subjects: 2466

Group type: COMPARATOR
Intervention: Placebo (n = 1232)
Number of subjects: 2466

Group type: EXPERIMENTAL
Intervention: Diltiazem in patients without pulmonary congestion (n = 1909)
Number of subjects: 2466

Group type: EXPERIMENTAL
Intervention: Diltiazem in patients with pulmonary congestion (n = 490)
Number of subjects: 2466
Study: 31270933

Group type: EXPERIMENTAL
Intervention: Interaction trees (IT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simultaneous threshold interaction modeling algorithm (STIMA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Model‐based recursive partitioning
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subgroup identification based on differential effect
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adaptive refinement by directed peeling
Number of subjects: 0

Group type: COMPARATOR
Intervention: None of the methods
Number of subjects: 0
Study: 29473382

Group type: COMPARATOR
Intervention: Solifenacin Succinate (SS), 5 mg once a day for 12 weeks
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Complementary and Alternative Medicine (CAM), 930 mg twice daily for 12 weeks
Number of subjects: 90
Study: 25152207

Group type: EXPERIMENTAL
Intervention: Telbivudine plus PegIFN alpha‐2a (combination therapy)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Telbivudine monotherapy
Number of subjects: 159

Group type: COMPARATOR
Intervention: PegIFN alpha‐2a monotherapy
Number of subjects: 159
Study: 23084597

Group type: EXPERIMENTAL
Intervention: MICA v4 scale
Number of subjects: 191
Study: 21211688

Group type: EXPERIMENTAL
Intervention: Device-detected atrial tachycardia (AT) or atrial fibrillation (AF) >10 min
Number of subjects: 1193

Group type: EXPERIMENTAL
Intervention: Composite end point (deaths or HF hospitalizations)
Number of subjects: 1193

Group type: EXPERIMENTAL
Intervention: Device-detected AT/AF
Number of subjects: 1193

Group type: EXPERIMENTAL
Intervention: New York Heart Association functional class III or IV compared with II
Number of subjects: 1193

Group type: EXPERIMENTAL
Intervention: Absence of beta-blockers
Number of subjects: 1193

Group type: EXPERIMENTAL
Intervention: Left ventricular ejection fraction
Number of subjects: 1193
Study: 18241759

Group type: EXPERIMENTAL
Intervention: Endovascular treatment (carotid artery stenting)
Number of subjects: 2985

Group type: COMPARATOR
Intervention: Surgical treatment (carotid endarterectomy)
Number of subjects: 2985
Study: 16167251

Group type: EXPERIMENTAL
Intervention: Titanoreine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (no titanoreine)
Number of subjects: 80
Study: 12491829

Group type: EXPERIMENTAL
Intervention: Early enteral feeding (EEF)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Total parenteral nutrition plus enteral feeding (TPN + EF)
Number of subjects: 28
Study: 9751347

Group type: EXPERIMENTAL
Intervention: Boxer shorts
Number of subjects: 97

Group type: COMPARATOR
Intervention: Brief style underwear
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Crossover group (changed underwear type)
Number of subjects: 97
Study: 7714474

Group type: EXPERIMENTAL
Intervention: Coherent motion discrimination based on direction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coherent motion discrimination based on speed
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall sensitivity to coherent motion strength
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Processing of direction and speed information
Number of subjects: 0
Study: 2651586

Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 52

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Surgical treatment in semicomatose/stuporous patients
Number of subjects: 52

Group type: COMPARATOR
Intervention: Conservative treatment in semicomatose/stuporous patients
Number of subjects: 52
Study: 328033

Group type: EXPERIMENTAL
Intervention: Diflunisal 375 mg twice daily
Number of subjects: 740

Group type: COMPARATOR
Intervention: Glafenin 200 mg three times daily
Number of subjects: 740

Group type: COMPARATOR
Intervention: Acetylsalicylic acid
Number of subjects: 740

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 740
Study: 30527775

Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 2199

Group type: COMPARATOR
Intervention: Enoxaparin–warfarin
Number of subjects: 2199
Study: 29657693

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Routine psychological counseling services (Control)
Number of subjects: 70
Study: 25742985

Group type: EXPERIMENTAL
Intervention: Natalizumab
Number of subjects: 25

Group type: COMPARATOR
Intervention: Interferon‐β/glatiramer acetate
Number of subjects: 25